Thrombosis in thrombocythemic Ph-myeloproliferations is
associated with higher platelet count prior to the event:
results of analyses of prothrombotic risk factors from a
registry of patients treated with anagrelide

J 2016

Thrombosis in thrombocythemic Ph-myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

SCHWARZ, Jiří, Petra OVESNÁ, Olga ČERNÁ, Jarmila KISSOVÁ, Jacqueline SOUKUPOVÁ MAALOUFOVÁ et. al.

Základní údaje

Originální název

Thrombosis in thrombocythemic Ph-myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

Autoři

SCHWARZ, Jiří (203 Česká republika), Petra OVESNÁ (203 Česká republika, domácí), Olga ČERNÁ (203 Česká republika), Jarmila KISSOVÁ (203 Česká republika, domácí), Jacqueline SOUKUPOVÁ MAALOUFOVÁ (203 Česká republika), Yvona BRYCHTOVÁ (203 Česká republika), Michael DOUBEK (203 Česká republika, domácí), Libor ČERVINEK (203 Česká republika, domácí), Eduard CMUNT (203 Česká republika), Petr DULÍČEK (203 Česká republika), Vít CAMPR (203 Česká republika), Leoš KŘEN (203 Česká republika, domácí) a Miroslav PENKA (203 Česká republika, garant, domácí)

Vydání

European Journal of Haematology, Hoboken, Wiley-Blackwell, 2016, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.653

Kód RIV

RIV/00216224:14110/16:00089657

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/ejh.12554

UT WoS

000367920800016

EID Scopus

2-s2.0-84955193963

Klíčová slova anglicky

myeloproliferative disorders; platelets; JAK2; thrombophilia; thrombosis; anagrelide

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 8. 2016 16:32, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Controversies still exist regarding definition of the thrombotic risks in Ph-(BCR/ABL1-) myeloproliferative disorders with thrombocythemia (MPD-T). Platelet counts at diagnosis are currently not taken as a risk factor of thrombosis. In our cohort of 1179 patients with MPD-T, prospectively registered for anagrelide treatment, we found that the median platelet count prior to the thrombotic event was significantly higher than at time points without any ensuing thrombosis (453 vs. 400 9 10(9)/L, P < 0.001), albeit higher platelet counts at diagnosis tended to be connected with fewer thrombotic events (in contrast to WBC counts at diagnosis). The JAK2(V617F) mutation predicted both arterial and venous events, while age >65 yr, hypertension, diabetes mellitus, smoking, elevated triglyceride and homocysteine levels predicted arterial events only. For venous events, the specific thrombophilic risk factors (factor V `Leiden' and others), antiphospholipid antibodies, and elevated factor VIII levels played a major role. During anagrelide treatment (+/- aspirin), we documented a decrease in both venous (6.7-fold) and arterial events (1.8-fold), while bleeding (mostly minor events) increased twofold compared to history. Our results suggest that keeping platelet counts at low levels may be a meaningful therapeutic measure to prevent thrombosis, although their counts at diagnosis lack any prognostic value.

Přiložené soubory

EL_1341786.pdf

Požádat o autorskou verzi souboru

Citovat

SCHWARZ, Jiří, Petra OVESNÁ, Olga ČERNÁ, Jarmila KISSOVÁ, Jacqueline SOUKUPOVÁ MAALOUFOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Libor ČERVINEK, Eduard CMUNT, Petr DULÍČEK, Vít CAMPR, Leoš KŘEN a Miroslav PENKA. Thrombosis in thrombocythemic Ph-myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. European Journal of Haematology. Hoboken: Wiley-Blackwell, 2016, roč. 96, č. 1, s. 98-106. ISSN 0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12554.

@article{1341786,
   author = {Schwarz, Jiří and Ovesná, Petra and Černá, Olga and Kissová, Jarmila and Soukupová Maaloufová, Jacqueline and Brychtová, Yvona and Doubek, Michael and Červinek, Libor and Cmunt, Eduard and Dulíček, Petr and Campr, Vít and Křen, Leoš and Penka, Miroslav},
   article_location = {Hoboken},
   article_number = {1},
   doi = {http://dx.doi.org/10.1111/ejh.12554},
   keywords = {myeloproliferative disorders; platelets; JAK2; thrombophilia; thrombosis; anagrelide},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Thrombosis in thrombocythemic Ph-myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide},
   volume = {96},
   year = {2016}
}

TY  - JOUR
ID  - 1341786
AU  - Schwarz, Jiří - Ovesná, Petra - Černá, Olga - Kissová, Jarmila - Soukupová Maaloufová, Jacqueline - Brychtová, Yvona - Doubek, Michael - Červinek, Libor - Cmunt, Eduard - Dulíček, Petr - Campr, Vít - Křen, Leoš - Penka, Miroslav
PY  - 2016
TI  - Thrombosis in thrombocythemic Ph-myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide
JF  - European Journal of Haematology
VL  - 96
IS  - 1
SP  - 98-106
EP  - 98-106
PB  - Wiley-Blackwell
SN  - 09024441
KW  - myeloproliferative disorders
KW  - platelets
KW  - JAK2
KW  - thrombophilia
KW  - thrombosis
KW  - anagrelide
N2  - Controversies still exist regarding definition of the thrombotic risks in Ph-(BCR/ABL1-) myeloproliferative disorders with thrombocythemia (MPD-T). Platelet counts at diagnosis are currently not taken as a risk factor of thrombosis. In our cohort of 1179 patients with MPD-T, prospectively registered for anagrelide treatment, we found that the median platelet count prior to the thrombotic event was significantly higher than at time points without any ensuing thrombosis (453 vs. 400 9 10(9)/L, P < 0.001), albeit higher platelet counts at diagnosis tended to be connected with fewer thrombotic events (in contrast to WBC counts at diagnosis). The JAK2(V617F) mutation predicted both arterial and venous events, while age >65 yr, hypertension, diabetes mellitus, smoking, elevated triglyceride and homocysteine levels predicted arterial events only. For venous events, the specific thrombophilic risk factors (factor V `Leiden' and others), antiphospholipid antibodies, and elevated factor VIII levels played a major role. During anagrelide treatment (+/- aspirin), we documented a decrease in both venous (6.7-fold) and arterial events (1.8-fold), while bleeding (mostly minor events) increased twofold compared to history. Our results suggest that keeping platelet counts at low levels may be a meaningful therapeutic measure to prevent thrombosis, although their counts at diagnosis lack any prognostic value.
ER  -

SCHWARZ, Jiří, Petra OVESNÁ, Olga ČERNÁ, Jarmila KISSOVÁ, Jacqueline SOUKUPOVÁ MAALOUFOVÁ, Yvona BRYCHTOVÁ, Michael DOUBEK, Libor ČERVINEK, Eduard CMUNT, Petr DULÍČEK, Vít CAMPR, Leoš KŘEN a Miroslav PENKA. Thrombosis in thrombocythemic Ph-myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. \textit{European Journal of Haematology}. Hoboken: Wiley-Blackwell, 2016, roč.~96, č.~1, s.~98-106. ISSN~0902-4441. Dostupné z: https://dx.doi.org/10.1111/ejh.12554.

Přehled o publikaci